Greenstone Wins NIH Grant for AI Drug Discovery
Greenstone’s NIH-backed programme shows how AI drug discovery is moving toward better disease models, not just molecule generation.
AI drug discovery is not only about finding new molecules faster. It also depends on whether the lab models are realistic enough to trust.
What happened
Greenstone Biosciences received an NIH Catalyze R61 award to advance a drug-discovery programme for cardiac fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy.
The company combines iPSC biobanks, omics, disease models and AI-driven screening to identify potential therapeutics. The grant is not a venture round, but it supports a specific translational research programme in a serious disease area.
Why it matters
Drug discovery often fails because promising early results do not translate into humans. Greenstone’s approach focuses on more human-relevant disease models, using patient-derived biological systems and AI screening to improve the quality of early discovery work.
That makes this less of a “AI finds miracle drug” story and more of an infrastructure story. Better models, better data and better screening can improve the odds before expensive clinical development begins.
The bigger picture
Life-sciences AI is maturing beyond the first wave of molecule-design hype. The next layer is full-stack discovery infrastructure: biobanks, disease modelling, robotic labs, omics and computational screening working together. Greenstone’s grant points to that broader shift.